Literature DB >> 8518095

Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients.

P Niaudet1, G Jean, M Broyer, L Chatenoud.   

Abstract

The anti-OKT3 response was studied in 40 paediatric kidney transplant recipients receiving OTK3 as a prophylactic treatment in association with azathioprine and prednisone. Only 1 patient experienced a reversible acute rejection episode while receiving OKT3. OKT3 induced a rapid disappearance of CD3+ cells, but significant proportions of CD3+ cells reappeared before the end of the treatment in 14 patients. Wide variations in circulating OKT3 levels were observed and in only 50% of patients could stable circulating OKT3 levels be detected until discontinuation of treatment. Anti-OKT3 antibodies detected by the enzyme-linked immunosorbent assay (ELISA) (anti-idiotypic and anti-isotypic antibodies) developed in 91% of patients. Anti-idiotypic antibodies detected by the immunofluorescence inhibition test were found in the sera of 71% of patients, always when high titres of anti-OKT3 antibodies were detected by ELISA. As it has recently been shown that anti-idiotypic antibodies are associated with failure of subsequent OKT3 treatment, we conclude that OKT3 should be restricted to steroid-resistant rejection crises in paediatric patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8518095     DOI: 10.1007/BF00853215

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  20 in total

Review 1.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

2.  Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients.

Authors:  M R Leone; J M Barry; S R Alexander; T Melvin; J Striegel; K Reller; K R Henell; J Kimball; M B Funnell; G Goldstein
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

3.  Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.

Authors:  P Vigeral; N Chkoff; L Chatenoud; H Campos; M Lacombe; D Droz; G Goldstein; J F Bach; H Kreis
Journal:  Transplantation       Date:  1986-06       Impact factor: 4.939

4.  Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection.

Authors:  D J Norman; C F Shield; K R Henell; J Kimball; J M Barry; W M Bennett; M Leone
Journal:  Transplantation       Date:  1988-10       Impact factor: 4.939

5.  A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection.

Authors:  J O Colonna; L I Goldstein; J J Brems; J H Vargas; J E Brill; W J Berquist; J R Hiatt; R W Busuttil
Journal:  Arch Surg       Date:  1987-10

6.  Inhibition of anti-OKT3 antibody generation by cyclosporine--results of a prospective randomized trial.

Authors:  D E Hricik; J T Mayes; J A Schulak
Journal:  Transplantation       Date:  1990-08       Impact factor: 4.939

7.  [A comparative trial of OKT3 and antilymphocyte serum in the preventive treatment of rejection after kidney transplantation in children].

Authors:  P Niaudet; I Murcia; G Jean; M Broyer
Journal:  Ann Pediatr (Paris)       Date:  1990-02

8.  Reexposure to OKT3 in renal allograft recipients.

Authors:  J T Mayes; J R Thistlethwaite; J K Stuart; M R Buckingham; F P Stuart
Journal:  Transplantation       Date:  1988-02       Impact factor: 4.939

9.  Prediction of successful allograft rejection retreatment with OKT3.

Authors:  C Legendre; H Kreis; J F Bach; L Chatenoud
Journal:  Transplantation       Date:  1992-01       Impact factor: 4.939

10.  Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3.

Authors:  L Chatenoud; M F Baudrihaye; N Chkoff; H Kreis; G Goldstein; J F Bach
Journal:  J Immunol       Date:  1986-08-01       Impact factor: 5.422

View more
  2 in total

Review 1.  Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 2.  Immunogenicity of Protein Therapeutics: A Lymph Node Perspective.

Authors:  Kristy Fu; Kylie March; Aikaterini Alexaki; Giulia Fabozzi; Eirini Moysi; Constantinos Petrovas
Journal:  Front Immunol       Date:  2020-05-14       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.